Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EDP-305 in Healthy and Presumptive NAFLD Subjects
NCT02918929Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP-305 in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Safety data including adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results. Started Sep 2016; status: completed.
02
Drugs
EDP-305
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02918929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918929.